Drugs / Adipose derived mesenchymal stromal cells
Adipose derived mesenchymal stromal cells
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT06649864 | Feb 2027 → Jan 2028 expected | liver disorder | Mayo Clinic | Not yet recruiting | No outcome recorded |
| Comparator or background therapy1 trial | ||||||
| Phase 1/2 | NCT04714801 Comparator | Oct 2020 → Nov 2023 | transplant rejection | Rigshospitalet, Denmark | Unknown | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Adipose derived mesenchymal stromal cells | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06649864 ↗ |
| Known as | AMSC | “Autologous adipose derived mesenchymal stromal cells (AMSC)” NCT06649864 ↗ |
| Known as | ASCs | “allogeneic adipose tissue-derived stromal cells (ASCs), as an add-on therapy” PMID 40247997 ↗ Mar 2025 |
| Modality | Cell therapy | “stem cell therapy” NCT04714801 ↗ |
| Route | Intravenous | “intravenous infusion of either ASCs or placebo within two hours after lung transplantation” PMID 40247997 ↗ Mar 2025 |